The Full Wiki

More info on LY-334,370

LY-334,370: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

LY-334,370
LY334370.png
IUPAC name
Other names LY-334,370
Identifiers
CAS number 182563-08-2
PubChem 5311258
SMILES
Properties
Molecular formula C21H22FN3O
Molar mass 351.42 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

LY-334,370 is a selective 5-HT1F receptor agonist[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.[4]

References

  1. ^ Dupuis DS, Colpaert FC, Pauwels PJ (1998). "G-protein activation at 5-HT1A receptors by the 5-HT1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines". Br. J. Pharmacol. 124 (2): 283–90. doi:10.1038/sj.bjp.0701832. PMID 9641544.  
  2. ^ Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). "Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY-334,370". Cephalalgia 19 (10): 851–8. doi:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103.  
  3. ^ Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). "Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial". Lancet 358 (9289): 1230–4. doi:10.1016/S0140-6736(01)06347-4. PMID 11675061.  
  4. ^ Ramadan NM, Buchanan TM (2006). "New and future migraine therapy". Pharmacol. Ther. 112 (1): 199–212. doi:10.1016/j.pharmthera.2005.04.010. PMID 16797716.  

External links








Got something to say? Make a comment.
Your name
Your email address
Message